Table 1 Selected CAR- and TCR-modified T-cell trials with clinical testing sites in Germany.
From: Retroviral gene therapy in Germany with a view on previous experience and future perspectives
Disease | Sponsor | Trial sites in Germany | Trial number |
|---|---|---|---|
CAR T-cell studies | |||
Hematologic and lymphatic malignancies positive for CD123 | Cellex Patient Treatment GmbH | University Hospital Ulm University Hospital Würzburg Philipps-University Marburg University Hospital Dresden University Hospital Leipzig | |
Relapsed/Resistant CD20 positive B-NHL | Miltenyi Biomedicine GmbH | University Hospital Cologne University Hospital Leipzig | |
MM | Janssen Research & Development, LLC | University Hospital Hamburg Eppendorf University Hospital Heidelberg University Hospital Würzburg | |
Metastatic melanoma | Miltenyi Biomedicine GmbH and DLR German Aerospace Center | University Hospital of Cologne | |
Relapsed/refractory CD19 positive B-cell malignancies | Miltenyi Biomedicine GmbH | University Hospital Erlangen University Hospital Münster | |
Relapsed and lenalidomide-refractory MM | Janssen Research & Development, LLC | University Hospital Carl Gustav Carus Dresden at the Technical University of Dresden University Hospital Hamburg Eppendorf University Hospital Heidelberg University Hospital Cologne University Hospital Leipzig Eberhard-Karls-University Hospital University Hospital Würzburg | |
Relapsed/refractory MM | Celgene | University Hospital Heidelberg University of Tübingen University Hospital Würzburg | |
Relapsed/refractory MM (KarMMa-3) | Celgene | University Hospital Heidelberg University Hospital Cologne University Hospital Würzburg | |
Relapsed/refractory DLBCL | Novartis Pharmaceuticals | Novartis investigative sites (Cologne, Würzburg) | |
Refractory/relapsed FL | Novartis Pharmaceuticals | Novartis investigative sites (Cologne, Münich, Ulm) | |
Relapsed/refractory CLL | Kite, A Gilead Company | University Hospital Heidelberg | |
Relapsed/refractory DLBCL or other aggressive B-cell malignancies | Celgene | Medizinische Klinik und Poliklinik I (Dresden) University Hospital Heidelberg University of Cologne MU Klinikum der Universität (Munich) Universitatsklinikum Ulm | |
Refractory aggressive NHL | Kite, A Gilead Company | University Hospital Dresden University Hospital of Essen University Hospital Würzburg | |
Relapsed/refractory DLBCL (ZUMA-7) | Kite, A Gilead Company | University Hospital Dresden University Hospital Gottingen University Hospital Hamburg-Eppendorf University Hospital Heidelberg University Hospital Munster University Hospital Würzburg | |
MB-CART2019.1 in patients with relapsed or resistant CD20 and CD19 positive B-NHL | Miltenyi Biomedicine GmbH | University Hospital Augsburg University Hospital Cologne University Hospital Hamburg-Eppendorf | |
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-NHL (BELINDA) | Novartis Pharmaceuticals | Novartis investigative sites (Regensburg, Berlin, Hamburg, Cologne, Leipzig, Münich, Ulm) | |
JCAR017 compared to standard of care in adult patients with high-risk, second-line, transplant-eligible relapsed or refractory aggressive B-NHL (TRANSFORM) | Celgene | Robert-Rössle-Clinic in HELIOS Clinic Berlin-Buch Clinic University Hospital Carl Gustav Carus Dresden University Hospital Hamburg-Eppendorf University of Cologne University Hospital Munster LMU Clinic at University of Münich | |
Safety and efficacy of allogeneic CRISPR-Cas9-engineered T cells (CTX110) in patients with relapsed or refractory B-cell malignancies (CRSP-ONC-001) | CRISPR Therapeutics AG | University of Hamburg | |
TCR-modified T-cell studies | |||
High-risk myeloid and lymphoid neoplasms (CD-TCR-001) | Medigene AG | University Hospital Dresden University Hospital Erlangen University Hospital Frankfurt University Hospital Freiburg University Hospital Heidelberg University Hospital Leipzig University Hospital Mainz University Hospital Regensburg University Hospital Würzburg | |
Adult solid tumors | Immatics US, Inc. | University Hospital Würzburg University Hospital Bonn University Hospital C.-G.-Carus Dresden | |
WT1 TCR therapy in MDS or AML patients who failed to achieve or maintain an IWG response following hypomethylating agent therapy | Cell Medica Ltd | University Hospital Dresden | |
